Cell & Gene Collaborative Blog

51. Autologous Cell Therapy Learnings Illuminate The Path To Allogeneic Manufacturing Platforms 2/15/2022

    This is where Wugen's Ken Chrobak, VP of CMC, and I started our conversation — in what ways the autologous space has informed Wugen’s pursuit of allogeneic therapies, and how Chrobak and his team have implemented these learnings into the work they’re doing today.

52. ARW's C&G Manufacturing Must-Reads (Valentine's Day Edition!) 2/11/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

53. “Ancillary Materials” 1/25/2022

    I just couldn’t keep these links to myself

54. 5 New Year's Resolutions For Advancing The CGT Manufacturing Paradigm 1/25/2022

    The resolutions in this article provide some best practices we can implement and/or knowledge with which we can equip ourselves in the upcoming year. This way, in a year’s time when we look back on 2022, we will have a firm baseline from which we can measure just how much more sophisticated the CGT manufacturing sector has become.  

55. CGT Manufacturing Resolution #5: Find Balance Between “The Sky Is Falling!” & “Surprise!” In Communicating Risks 1/20/2022

    In the fifth of this five-part article, Spink dives into resolution #5, urging companies to perfect the “what’s” “when’s” and “how’s” of communicating manufacturing risks in a “balanced manner” at the highest levels of a company.

56. CGT Manufacturing Resolution #4: “Work Backwards” When Capacity & Supply Chain Planning 1/18/2022

    In the fourth of this five-part article, Spink dives into resolution #4, outlining how companies can and should be approaching commercial-scale capacity planning from the earliest stages of development.

57. ARW's C&G Manufacturing Must-Reads ("Tabloid" Edition!) 1/14/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

58. “Ancillary Materials” 1/13/2022

    New year, new quality-of-life-improving shenanigans...

59. CGT Manufacturing Resolution #3: Embrace — Don't Fear— Deep Characterization Of Your Products 1/13/2022

    In the third of this five-part article, Dark Horse Consulting's Katy Spink dives into resolution #3, recommending that companies be analytically ambitious from the very beginning.

60. CGT Manufacturing Resolution #2: Explore Novel Partnership & Outsourcing Structures 1/11/2022

    In the second of this five-part article, Spink dives into New Year's manufacturing resolution #2, advising CGT companies to explore the increasingly wide variety of outsourcing and partnership models emerging to help companies collaboratively de-risk their manufacturing processes.